The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Evaluating treatment response following locoregional therapy for hepatocellular carcinoma: A review of the available serological and radiological tools for assessment
1Department of Surgery (Austin Precinct) The University of Melbourne Melbourne Victoria Australia.
2Hepatopancreatobiliary and Liver Transplant Surgery Unit Austin Health Melbourne Victoria Australia.
3Department of Medicine (Austin Precinct) The University of Melbourne Melbourne Victoria Australia.
4Liver Transplant Unit, Department of Gastroenterology and Hepatology Austin Health Melbourne Victoria Australia.
5Department of Radiology Austin Health Melbourne Victoria Australia.
6Department of Radiation Oncology Austin Health Melbourne Victoria Australia.
7School of Molecular Sciences, La Trobe University Melbourne Victoria Australia.
8Department of Medical Imaging and Radiation Sciences Monash University Melbourne Victoria Australia.
Abstract
Hepatocellular carcinoma (HCC) is an aggressive primary malignancy of the liver and is the third most common cause of cancer-related global mortality. There has been a steady increase in treatment options for HCC in recent years, including innovations in both curative and non-curative therapies. These advances have brought new challenges and necessary improvements in strategies of disease monitoring, to allow early detection of HCC recurrence. Current serological and radiological strategies for post-treatment monitoring and prognostication and their limitations will be discussed and evaluated in this review.
Stay Informed!
